Microglia modulate neurodegeneration in Alzheimer's and Parkinson's diseases

Tim Bartels1, Sebastiaan De Schepper1, Soyon Hong2

  • 1UK Dementia Research Institute, Institute of Neurology, University College London, London WC1E 6BT, UK.

Science (New York, N.Y.)
|October 2, 2020
PubMed

Insights

Microglia, the brain's immune cells, are crucial for neuronal health. Impaired communication between microglia and neurons may drive neurodegenerative diseases like Alzheimer's and Parkinson's.

Area of Science:

  • Neuroscience
  • Immunology
  • Neurodegenerative Diseases

Background:

  • Dementia represents a growing global health challenge with no current early diagnostic biomarkers or effective treatments.
  • Microglia, traditionally viewed as passive cells, are now recognized as active regulators of neuronal function and brain homeostasis.
  • Dysfunctional microglia-neuron interactions are implicated in the progression of neurodegenerative conditions.

Purpose of the Study:

  • To elucidate the fundamental role of microglia as tissue-resident macrophages in maintaining neuronal health.
  • To explore the hypothesis that chronic impairment in microglia-neuron cross-talk contributes to synaptic and neuronal dysfunction in Alzheimer's and Parkinson's diseases.
  • To emphasize the importance of understanding and modulating microglia-neuron interactions for developing dementia therapies.

Main Methods:

  • Review and synthesis of current literature on microglia function in the adult brain.
  • Analysis of the proposed mechanisms linking microglia-neuron communication deficits to neurodegeneration.
  • Conceptual framework development for assessing and modulating microglia-neuron interactions.

Main Results:

  • Microglia play a critical role in governing neuronal function and maintaining brain homeostasis.
  • Chronic impairment of microglia-neuron cross-talk is suggested as a key factor in the persistent failure of neuronal function observed in Alzheimer's and Parkinson's diseases.
  • Targeting microglia-neuron interactions presents a promising therapeutic avenue for dementia.

Conclusions:

  • Microglia are essential for neuronal health and synaptic function.
  • Defective microglia-neuron communication is a potential driver of dementia pathogenesis.
  • Developing strategies to assess and modulate these interactions is crucial for future dementia therapies.

Related Concept Videos

Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
42.6K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.5K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.4K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
630